PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.35%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
117.22%
Other expenses growth 1.1-1.25x CRVO's 100.00%. Bill Ackman would demand expense justification.
89.95%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
89.95%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
-4.24%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
100.53%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
79.29%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-95.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-104.55%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-100.00%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.40%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-134.36%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-134.21%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-134.21%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.